Dopamine receptor agonist and anti-Parkinson's agent. Displays high affinity for D2
receptors along with 5-HT1A
. Exhibits some 5-HT2B
receptor antagonist properties. Decreases prolactin release; reduces inflammatory mediators such as TNF-α
and IL6. Exhibits anticonvulsive effects. Acts similar to bromocriptine
(Cat. No. 0427).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fi
Hofmann et al.
Anticonvulsive effects of the dopamine agonist lisuride maleate after experimental traumatic brain injury.
Zweckberger et al.
Transdermal lisuride delivery in the treatment of Parkinson's disease.
Woitalla et al.
J.Neural Transm., 2004;68:89